文献速递艾滋病与性传播感染病毒性肝炎

ICONA队列:初治HIV感染者ART后肝酶升高的发生率与危险因素

Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort.
PubMed 文献 · J Antimicrob Chemother · 2019-01-01

调整混杂后,INSTI较NNRTI的肝酶升高风险减半(HR 0.46,95%CI 0.25-0.86),合并HBV/HCV感染及HIV控制不佳者风险更高。

要点

  • INSTI方案较NNRTI方案肝酶升高风险减半(HR 0.46,95%CI 0.25-0.86)。
  • 合并HBV或HCV感染、HIV控制不佳者肝酶升高风险显著更高。
  • 对肝毒性高风险患者,选择INSTI方案可能尤为重要。

核心结论

  • INSTI方案较其他方案几乎使肝酶升高风险减半,对合并HCV/HBV等肝毒性风险因素者选择ART尤其重要。

主要发现

  • 调整主要混杂因素后,INSTI较NNRTI的肝酶升高风险减半(HR 0.46,95%CI 0.25-0.86)。
  • 以NNRTI类为参照,raltegravir组肝酶升高风险显著降低(HR 0.11,95%CI 0.02-0.84)。
  • 合并HBV或HCV感染、HIV控制不佳及经同性传播感染HIV者肝酶升高HR显著更高。

关键数值与推荐

  • 肝酶升高定义为基线正常者ALT或AST≥2.5×正常上限(ULN),或基线较高者≥2.5×基线值。
  • 研究人群中HBV表面抗原阳性占3.9%,HCV RNA阳性占5.8%。

临床怎么用

  • 初治HIV感染者选择ART时,对合并HBV/HCV感染或HIV控制不佳等肝毒性高风险者,可优先考虑INSTI方案以降低肝酶升高风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the incidence and risk factors for liver enzyme elevations (LEE) in patients initiating first-line ART in the ICONA prospective observational cohort, between June 2009 and December 2017. PATIENTS AND METHODS: In total, 6575 ART-naive patients were selected, initiating two NRTIs with the third drug being a boosted PI (n=2436; 37.0%), an NNRTI (n=2384; 36.3%) or an integrase strand transfer inhibitor (INSTI) (n=1755; 26.7%). HBV surface antigen and HCV RNA were detected in 3.9% and 5.8% of the study population. Inverse probability weighted Cox regression analysis was used to calculate the HRs, according to first-line regimen, for LEE, defined as ALT or AST increases of ≥2.5× upper limit of normal (ULN) for patients with normal baseline values or ≥2.5× baseline for patients with higher baseline values. RESULTS: One hundred and eighty-three LEE occurred over 20722 patient-years of follow-up. After adjusting for the main confounders, the risk of LEE halved with INSTIs compared with NNRTIs (HR 0.46, 95% CI 0.25-0.86), with a significant reduction in the raltegravir group (HR 0.11, 95% CI 0.02-0.84 using the NNRTI class as reference). HRs for LEE were significantly higher in subjects with HBV or HCV coinfection, in patients with poorly controlled HIV infection and in those who acquired HIV through homosexual transmission. CONCLUSIONS: In our study, INSTI use almost halved the risk of LEE compared with other regimens. This finding could be particularly important for choosing ART in patients with risk factors for liver toxicity such as HCV and HBV coinfections.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Taramasso L, Lorenzini P, Di Biagio A, et al. Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort. J Antimicrob Chemother. 2019. PMID: 31504633. doi:10.1093/jac/dkz353

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。